Business
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractor...
About this update from Heidelberg Pharma Ag
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma.","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST)","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":342,"olType":false},{"type":"text","content":"LADENBURG, Germany - November 3, 2025 (NEWMEDIAWIRE) - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announced the presentation of new clinical data from its ongoing Phase I/IIa clinical study evaluating its lead Amanitin-based ADC candidate, HDP-101 (INN: pamlectabart tismanitin), at the 16th Annual World ADC Congress, taking place in San Diego, California, from 3 to 6 November 2025.","length":455,"tagName":"p"},{"type":"text","content":"HDP-101 (INN: pamlectabart tismanitin) is an anti-BCMA antibody-drug conjugate being investigated for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with a high unmet medical need. Phase I of the ongoing study is a dose-escalation trial designed to determine the optimal and safe dose level of HDP-101 in preparation for subsequent Phase II clinical evaluation.","length":393,"tagName":"p"},{"type":"text","content":"Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present an update from patient cohort 8 including efficacy data of the open-label, multicenter Phase I/IIa study evaluating HDP-101 in patients with relapsed or refractory multiple myeloma.","length":264,"tagName":"p"},{"type":"text","content":"Details of the presentation at 16th Annual World ADC Congress:","length":62,"tagName":"p"},{"type":"text","content":"Presentation title: From Bench to Breakthrough: The Evolution of Amanitin ADCs - Insights from HDP-101 Phase I/II & the Future of Payload Differentiation","length":157,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"text","content":"Speaker:","lengt...